PT2968368T - Administração craniana de substâncias farmacêuticas - Google Patents

Administração craniana de substâncias farmacêuticas

Info

Publication number
PT2968368T
PT2968368T PT147682231T PT14768223T PT2968368T PT 2968368 T PT2968368 T PT 2968368T PT 147682231 T PT147682231 T PT 147682231T PT 14768223 T PT14768223 T PT 14768223T PT 2968368 T PT2968368 T PT 2968368T
Authority
PT
Portugal
Prior art keywords
pharmaceutical substances
cranial administration
cranial
administration
pharmaceutical
Prior art date
Application number
PT147682231T
Other languages
English (en)
Portuguese (pt)
Inventor
Chang Wei-Wei
I Sawyer Kenneth
Original Assignee
Glia Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glia Llc filed Critical Glia Llc
Publication of PT2968368T publication Critical patent/PT2968368T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT147682231T 2013-03-15 2014-03-14 Administração craniana de substâncias farmacêuticas PT2968368T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361790120P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PT2968368T true PT2968368T (pt) 2017-11-15

Family

ID=51581702

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147682231T PT2968368T (pt) 2013-03-15 2014-03-14 Administração craniana de substâncias farmacêuticas

Country Status (13)

Country Link
US (2) US9682032B2 (enExample)
EP (1) EP2968368B1 (enExample)
JP (1) JP6317805B2 (enExample)
CN (1) CN105188708B (enExample)
AU (1) AU2014239842B2 (enExample)
BR (1) BR112015023694B1 (enExample)
CA (1) CA2909490C (enExample)
ES (1) ES2649730T3 (enExample)
HU (1) HUE034886T2 (enExample)
MX (1) MX2015013186A (enExample)
PT (1) PT2968368T (enExample)
TW (1) TWI636785B (enExample)
WO (1) WO2014152385A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504645B2 (en) 2014-10-20 2016-11-29 Oyster Point Pharma, Inc. Pharmaceutical formulations for treating ocular conditions
US10456435B2 (en) 2015-07-15 2019-10-29 Christopher A. MCELVANY Topical antiviral formulations and methods of using the same
IL265225B (en) * 2016-09-07 2022-08-01 Glia Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
WO2020014072A1 (en) * 2018-07-09 2020-01-16 Gt Biopharma, Inc. Neostigmine pharmaceutical combination for treating myasthenia gravis
CN109172580B (zh) * 2018-09-06 2021-04-27 中山万汉制药有限公司 包含前列腺素衍生物的组合物以及包含该组合物的眼用液体制剂
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
US20230091716A1 (en) * 2020-02-12 2023-03-23 Glia, Llc Progesterone Combinations
US12036228B2 (en) 2022-04-12 2024-07-16 Shackelford Pharma Inc. Treatment of seizure disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766988B2 (en) 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
US6610674B1 (en) 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
US20060089408A1 (en) * 2004-10-22 2006-04-27 Wei Ted C Jr Method of treating blepharospasm with a prostaglandin derivative
US20080132475A1 (en) 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
JP2011502152A (ja) * 2007-10-31 2011-01-20 パメラ リプキン プロスタグランジン類似体組成物及び上皮関連症状の治療方法
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
US8236768B2 (en) * 2008-10-03 2012-08-07 3B Pharmaceuticals, Inc. Topical antiviral formulations
WO2011055383A2 (en) * 2009-11-06 2011-05-12 Lyka Labs Limited Intranasal delivery to improve the performance of children suffering from dyslexia
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
HUE046963T2 (hu) 2012-07-27 2020-04-28 Glia Llc Készítmények és kezelés szembetegségekhez és rendellenességekhez

Also Published As

Publication number Publication date
TWI636785B (zh) 2018-10-01
US20160030333A1 (en) 2016-02-04
CA2909490C (en) 2021-07-13
HUE034886T2 (hu) 2018-03-28
US20170281531A1 (en) 2017-10-05
AU2014239842B2 (en) 2018-07-19
WO2014152385A2 (en) 2014-09-25
CN105188708B (zh) 2019-06-28
WO2014152385A3 (en) 2014-12-11
EP2968368B1 (en) 2017-08-09
TW201513867A (zh) 2015-04-16
CN105188708A (zh) 2015-12-23
MX2015013186A (es) 2016-04-15
JP6317805B2 (ja) 2018-04-25
BR112015023694B1 (pt) 2021-05-25
US9682032B2 (en) 2017-06-20
EP2968368A4 (en) 2016-10-12
US10251835B2 (en) 2019-04-09
JP2016513691A (ja) 2016-05-16
HK1213202A1 (zh) 2016-06-30
ES2649730T3 (es) 2018-01-15
AU2014239842A1 (en) 2015-11-05
CA2909490A1 (en) 2014-09-25
EP2968368A2 (en) 2016-01-20
BR112015023694A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
PT3030262T (pt) Composição farmacêutica de associação
DK3639872T3 (da) Lægemiddeladministrationsanordning
BR112016009485A2 (pt) Inalador de medicamento
HRP20180684T1 (hr) Kombinacija lijekova
ME03465B (me) Farmaceutska kompozicija s-ketamin hidrohlorida
DK3099356T3 (da) Medikamentadministrationsanordning
EP4005604C0 (en) ADMINISTRATION OF MEDICINES
DK3038674T3 (da) Medikamentafgivelsesindretning
PT2968368T (pt) Administração craniana de substâncias farmacêuticas
DK3380139T3 (da) Medikamentadministrationsanordning
HUE050779T2 (hu) Folyékony gyógyszerészeti készítmény
ZA201507576B (en) Pharmaceutical combination drug
DK3079655T3 (da) Inhalerbare lægemidler
DK2964193T3 (da) Lægemidler til oral indgivelse
DK3021911T3 (da) Anordning til indgivelse af lægemidler
DK3349825T3 (da) Lægemiddeladministrationsanordning
DK3349827T3 (da) Lægemiddeladministrationsanordning
IL245705B (en) Pharmaceutical dosage forms
DK3003401T3 (da) Farmaceutisk præparat
DK3148618T3 (da) Lægemiddeladministrationsanordning til administration af to medikamenter
DK3046537T3 (da) Farmaceutisk fremstilling af kulhydrater til terapeutisk anvendelse
DK2897588T3 (da) Inhalerbart lægemiddel
DK2983747T3 (da) Lægemiddelindgivelsesindretning
GB201319437D0 (en) Delivery of drugs